APA (7th ed.) Citation

Moore, K. N., Lorusso, D., Oaknin, A., Oza, A., Colombo, N., Van Gorp, T., . . . Matulonis, U. A. (2024). Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary. Gynecologic Oncology, 191, 249. https://doi.org/10.1016/j.ygyno.2024.10.013

Chicago Style (17th ed.) Citation

Moore, Kathleen N., et al. "Safety and Tolerability of Mirvetuximab Soravtansine Monotherapy for Folate Receptor Alpha–expressing Recurrent Ovarian Cancer: An Integrated Safety Summary." Gynecologic Oncology 191 (2024): 249. https://doi.org/10.1016/j.ygyno.2024.10.013.

MLA (9th ed.) Citation

Moore, Kathleen N., et al. "Safety and Tolerability of Mirvetuximab Soravtansine Monotherapy for Folate Receptor Alpha–expressing Recurrent Ovarian Cancer: An Integrated Safety Summary." Gynecologic Oncology, vol. 191, 2024, p. 249, https://doi.org/10.1016/j.ygyno.2024.10.013.